Background Human immunodeficiency virus (HIV) infection is the strongest risk factor for
developing tuberculosis and has fuelled its resurgence, especially in sub-Saharan Africa. In …

Drugs for tuberculosis are inadequate to address the many inherent and emerging
challenges of treatment. In the past decade, ten compounds have progressed into the …

Rapid expansion of the standardised approach to tuberculosis diagnosis and treatment that
is recommended by WHO allowed more than 36 million people to be cured between 1995 …

Vaccines to protect against tuberculosis (TB) are urgently needed. We performed a case–
control analysis to identify immune correlates of TB disease risk in Bacille Calmette–Guerin …

We can turn spinal cord injury from a threat into an opportunity. This has two dimensions.
First, spinal cord injury challenges almost every aspect of the health system. So enabling …

Background Mortality in people in Africa with HIV infection starting antiretroviral therapy
(ART) is high, particularly in those with advanced disease. We assessed the effect of a short …

Tuberculosis (TB) is an ancient disease, but not a disease of the past. After disappearing
from the world public health agenda in the 1960s and 1970s, TB returned in the early 1990s …

Like many other countries in Africa, Malawi is preparing to revise its policies for prevention of
mother-to-child transmission (PMTCT) of HIV and for antiretroviral therapy (ART) in response …

Background A crucial impediment to global tuberculosis control is the lack of an accurate,
rapid diagnostic test for detection of patients with active TB. A new, rapid diagnostic …

Efforts over the last 2 decades have led to a rich research and development pipeline of
tuberculosis (TB) vaccines. Although none of the candidates has successfully completed the …